Review the Agenda


Showcasing innovation across biotech, medtech and healthtech.

All time in GMT

Monday | Tuesday | Wednesday | Thursday | Friday | Monday


Monday 8th November


24hrs 1:1 video meetings - 24hrs across all timezone


24hrs Company showcases delivered on-demand 24/7



Tuesday 9th November


24hrs 1:1 video meetings - 24hrs across all timezone


24hrs Company showcases delivered on-demand 24/7


08:55 LSX Welcome

Josh Dance, SVP, LSX

Josh Dance, SVP, LSX


09:00 Keynote Presentation: Biotech In 2021 – Another Wave?

  • 2021 in review – a continued wave or a low tide?
  • The financing landscape: does venture funding and deal making continue to grow? Have IPOs exceed the 2020 performance?
  • Which types of innovations are attracting funding? Technology platforms and therapeutic areas attracting the greatest funding
  • How do investments change the industry structurally? How do changes in levels of financing and new sources impact the industry? (e.g., more biotechs launching products themselves)

Alexandra Zemp, Partner, McKinsey & Company
Joseph Lydon, Associate Partner, McKinsey & Company

Alexandra Zemp, Partner, McKinsey & Company    Joseph Lydon, Associate Partner, McKinsey & Company


10:00 Early-Stage Innovation And Investment – Saturation And Opportunity?

Early-stage investment in life sciences uncovers and funds the most promising new advances. But while the pandemic shifted the focus and funding to areas like anti-infectives, early disease detection, health and wellness, and remote care and telemedicine, and many companies pivoted in the fight, did this leave other opportunities behind? Which new areas of innovation in healthcare are emerging as the next wave and securing early-stage funding, and where do gaps remain?

  • Has Covid-19 caused an oversaturation of solutions targeted around the pandemic?
  • Have innovations in other areas been temporarily left behind?
  • Which areas are the most exciting investors in early-stage investment? Are platforms the key?

Martin Pfister, Principal, High-Tech Grunderfonds
Katja Rosenkranz, Partner, V-Bio Ventures
Diana Saraceni, Managing Partner, Panakès Partners
Montserrat Vendrell, Partner, Alta Life Sciences
Tassos Konstantinou, Investment Manager Life Sciences, IP Group

Martin Pfister, Investment Manager, High-Tech Gründerfonds    Katja Rosenkranz, Partner, V-Bio Ventures     Diana Saraceni, Co-Founder and General Partner, Panakes Partners     Montserrat Vendrell, General Partner, Alta Life Sciences     Tassos Konstantinou, Investment Manager Life Sciences, IP Gr


11:00 Masterclass: Protecting Your IP And Innovation

  • The importance of effectively protecting your innovation
    • What innovations should be protected and how?
    • The importance of timing good procedures and discipline
    • What investors will look for in terms of IP protection
  • Key IP pitfalls in research collaborations and partnerships and how to avoid them
    • Scope of licence
    • Financial terms – so many ways to skin the cat
    • IP ownership – avoiding deferral of challenging decisions
    • Milestones – how these evolve and how to avoid destructive disputes
    • Dispute resolution
  • Gaining maximum commercial benefit from your investment in R&D
    • Choosing the right collaboration partners
    • Keeping sufficient control over your investment
    • Identifying the opportunities, targets and markets.

Sally Shorthose, Partner, Bird & Bird
James Baillieu, Partner, Bird & Bird

Sally Shorthose, Partner, Bird & Bird    James Baillieu, Partner, Bird & Bird


12:00 Panel: Digital Health And Healthtech Investment – Can You Have Too Much Of A Good Thing?

As digital technology continues to converge with healthcare, expedited further by the pandemic, funding into digital health and advanced health technologies has seen huge growth in the last two years. Does more money mean more investors getting familiar in the space, deploying capital more regularly, and more digital talent moving into healthcare creating a more robust ecosystem against incumbent healthcare organisations? Or are too many companies getting too much funding, leading to difficulties in identifying the best scalable innovation? Could care delivery become more fragmented with competition for contracts and patient and consumer adoption? Future-focussed digital health investors discuss the evolution of the investment landscape and picking the right bets for delivering a more efficient and modern healthcare system.

  • Reviewing the success, growth and funding of the digital health and care ecosystem
  • Will the capital keep flowing in healthtech, or are we due for a slowdown and correction?
  • What are the strengths and weaknesses of the European digital innovation market compared with the US?

Tanja Dowe, CEO, Debiopharm Innovation Fund
David Germonpré, Partner, MTIP
Janke Dittmer, General Partner, Gilde Healthcare

Tanja Dowe, CEO, Debiopharm Innovation Fund SA    David Germonpré, Investment Partner, MTIP    Janke Dittmer, General Partner, Gilde Healthcare 300x


13:00 Masterclass: Planning & Implementing Successful Digital Health Projects

In this, the panel will discuss how to plan for and implement successful digital health projects, drawing on real world examples. Topics will include:

  • Effective ideation processes: asking the right diligence questions at the right time
  • Pharma/tech digital health collaborations fundamental compliance requirements
  • Collaborations with hospital systems: value for data, sensitivities in data ownership variability with hospitals in key commercial and regulatory topics
  • Practical considerations

Junaid Bajwa, Chief Medical Scientist, Microsoft Research
Daniel Pavin, Partner & Leader of Digital Health Initiative, Covington & Burling
Joshua Gray, Special Counsel, Covington & Burling

Junaid Bajwa, Chief Medical Scientist, Microsoft    Daniel Pavin, Partner, Covington & Burling    Joshua Gray, Special Counsel, Covington & Burling


14:00 Panel: Europe’s Healthcare Investment Landscape - Growing, Evolving, Consolidating?

While the pandemic presented many challenges early on, since late Q2 2020 investment skyrocketed, in almost all areas of healthcare. Previously perceived as risky, healthcare and biotech investments have become priorities for even conservative investors and the whole sector's shift has meant VCs have access to significant capital for large new funds and different vehicles, leading to a strong increase in funding for innovators. However, it broadly seems the larger VC firms are the ones growing and launching larger funds, whereas smaller fund managers are not finding raising new funds as easy. And Q2 of 2021 started to see a slowdown from exceptional Q1 levels. As we move through the tail end of the pandemic, how will the investment industry adapt and evolve? Europe's most active funds and investment leaders debate and discuss what this new normal looks like and what it means for investors, companies and the wider industry through 2022 and beyond.

  • With such a huge influx of capital, is there more competition for deals than ever?
  • Does Europe still offer the same advantages of being cheaper to operate, better value and more affordable valuations?
  • Are European companies thinking a lot earlier about their US presence than previously, are are investors advising them to do so?

Naveed Siddiqi, Senior Partner, Novo Ventures
Juliette Audet, Partner, Forbion Capital Partners
Florian Muellershausen, Managing Partner, Novartis Venture Fund
Bonnie Van Wilgenburg, Principal, Monograph Capital Partners
Houman Ashrafian, Managing Partner, SV Health Investors

Naveed Siddiqi, Partner, Novo Ventures, Novo Holdings AS    Juliette Audet, Partner, Forbion    Florian Muellershausen, Managing Director, Novartis Venture Fund    Bonnie Van Wilgenburg, Principal, Monograph Capital Partners    Houman Ashrafian, Managing Partner, SV Health Investors


15:00 Masterclass: Preparing For Your IPO – Strategies For Success

  • Initial considerations when planning an IPO
  • What type of listing is right for my company?
  • What are the key workstreams & timelines?
  • What happens post-IPO – continuing obligations
  • Going West – IPOs in the US
  • Going Dutch – IPOs on Euronext

Charles Waddell, Partner, Pinsent Masons
Roberta Markovina, Partner, Head of US Securities, Pinsent Masons
Sunjay Malhotra, Senior Associate, Pinsent Masons

Charles Waddell, Partner, Pinsent Masons    Roberta Markovina, Partner, Head of US Securities, Pinsent Masons    Sunjay Malhotra, Senior Associate, Pinsent Masons


16:00 Afternoon Keynote Panel: Starting With The End In Mind - Building A European As Well As US Commercial Strategy In Time To Make A Difference

With the majority of drug revenues coming from the US market, FDA approval is often the major, if not an exclusive, focus for smaller biotech and their investors early in their commercial planning. European market access and early commercial requirements can become an afterthought, or planned too late. As the US market becomes more challenging with payers and the drug pricing debate continues to evolve, biotech leadership teams and industry leading investors are questioning if a US-centric approach will continue to dominate, or if opportunities are being missed to maximise the potential of globally commercially viable assets. Executives and investors debate and discuss the importance of building concurrent US and European commercial strategy including:

  • Thinking early and robustly about US, European and even global commercial strategy
  • How investors build these considerations into their investment strategy and mindset
  • What leading investors can offer in terms of expertise and support to small biotech
  • How expanding focus beyond the US market can future proof your assets, boost global revenue potential, and enhance exit values

Tim Haines, Managing Partner, Abingworth
Gillian Cannon, Head of Commercial Innovation, Roivant Science
Erik van den Berg, CEO, AM Pharma
Joep Muijrers, General Partner, Gilde Healthcare
Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA
Moderator: Mel Walker, Managing Director, BioPharma Futures

Tim Haines, Chairman & Managing Partner, Abingworth LLP   Gillian Cannon, Head of Commercial Innovation, Roivant Science    Erik van den Berg, CEO, AM Pharma    Joep Muijrers, General Partner, Gilde Healthcare    Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA  Mel Walker, Managing Director, BioPharma Futures


17:00 Close Of Day 1 Content



Wednesday 10th November


24hrs 1:1 video meetings - 24hrs across all timezone


24hrs Company showcases delivered on-demand 24/7


08:55 LSX Welcome

Josh Dance, SVP, LSX

Josh Dance, SVP, LSX


09:00 Keynote Presentation: State Of The State

  • Robustness of the healthcare market
  • IPO market analysis and 2022 expectations
  • Healthcare market trends

Gil Bar-Nahum, Managing Director, Jefferies

Gil Bar-Nahum, MD Global Healthcare Investment Banking, Jefferies


10:00 Panel: Legal And Regulatory Considerations For Growth Investments – A Corporate And Investor Perspective



12:00 Masterclass: M&A - A Refresh For The Current Marke

  • Know your counter-party and competitors: from SPACs to private equity funds, knowing who your counter-party is and what their key drivers are is critical
  • Speed of execution: in this hotly contested market, being able to deliver deal certainty and fast can be a real competitive advantage
  • Outsourcing of risk: a significant amount of “sell side risk” is now being backed out to insurance or other parties, or is simply being negotiated away. Forewarned is forearmed as a buyer
  • Limiting tail end responsibility: particularly on carve-out or product divestments, TSA periods and the underlying periods are getting shorter and less all inclusive
  • Impact of FDI risks: national governments are keeping a more watchful eye over the life sciences sectors post-pandemic, both to preserve domestic capacity but also to ensure that potentially anti-competitive deals don’t get missed

Robbie McLaren, Partner Healthcare & Life Sciences Group, Latham & Watkins

Robbie McLaren, Partner, Latham & Watkins


13:00 Masterclass: SPACS

  • What are the pros and cons for companies considering a SPAC compared to a traditional IPO?
  • What makes a company attractive for a De-SPAC merger?
  • Are these vehicles, which have exploded in the US, to become increasingly commonplace in Europe?


14:00 Masterclass: Partnering, Business Development & Licensing

  • Market Trends & Drivers - early vs. late stage, therapeutic trends
  • Evolving collaborations - technology, big data, open innovation
  • Key considerations in licensing deals - the collaboration life cycle, formation issues, the impact of trends on deal terms, future-proofing deals


15:00 The Next Phase In US Healthcare Investment – What Have We Seen, And Where Are We Going?

From huge influxes of capital in early stage, growth and crossover rounds to record breaking IPOs at record speeds and the boom of SPACs; the US capital markets have seen a huge amount of volatility and shows little sign of slowing. How are leading US investor seeing the future of the US investment landscape?

  • Is investment keeping pace with innovation?
  • Will the IPO window and the SPACs boom continue?
  • Are we at an inflexion moment - how will the volatility shake out in 2022 and beyond?

William Hicks, Co-chair Securities & Capital Markets Group, Mintz
Scott Platshon, Partner, EcoR1 Capital
Travis Murdoch, Partner, Monograph Capital Partners
Stephanie Sirota, Partner and CBO, RTW Investments

William Hicks, Partner, Mintz Levin    Scott Platshon, Partner, EcoR1 Capital    Travis Murdoch, Partner, Monograph Capital Partners


16:00 Presentation: Opportunities In Iowa’s Onehealth Sector - Location Advantages For European Life Sciences Companies In The Midwest

Building a US presence at the right time is key for growing and internationalising European businesses. One Health is the integrative effort of multiple disciplines working locally, nationally, and globally to attain optimal health for people, animals, and the environment. Together, the three make up the One Health triad, and the health of each is inextricably connected to the others. Understanding and addressing the health issues created at this intersection is the foundation for the concept of One Health. The State of Iowa is well positioned, both, from a geographic as well as institutional and infrastructure position, to help businesses grow in this sector. This presentation will highlight:

  • Iowa’s assets in promoting the concept ‘One Health’
  • Location advantages for companies planning to expand in the Midwest
  • IEDA assistance and support programs

Mark Laurenzo, Business Development Manager, Iowa Economic Development Authority

Mark Laurenzo, Business Development Manager, Iowa Economic Development Authority



Thursday 11th November


24hrs 1:1 video meetings - 24hrs across all timezone


24hrs Company showcases delivered on-demand 24/7



Friday 12th November


24hrs 1:1 video meetings - 24hrs across all timezone


24hrs Company showcases delivered on-demand 24/7



Monday 15th November


08:30 1:1 Physical Partnering Hilton Waldorf London


18:00 In Person Networking Reception London

 

DOWNLOAD BROCHURE